Allows New Remedy for Arthritis
WASHINGTON (AP) — The Food and
Drug Administration approved a potential blockbuster
drug from Johnson & Johnson on Friday that fights three forms of arthritis caused by immune-system disorders.
The injectable medication, called Simponi, is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the United States by Johnson & Johnson and in Europe and other countries by the Schering-Plough Corporation.